Sangamo Therapeutics said the Food and Drug Administration has cleared its investigational new drug application for its ST-400 treatment for intractable pain due to idiopathic small fiber neuropathy.

The company states: “Sangamo (SGMO) Therapeutics announced that the FDA has cleared the investigational new drug application for its ST-503 program, an investigational epigenetic regulator for the ...

Albuquerque Acupuncture and Integrative Medicine is a local clinic specializing in treating complex chronic illnesses such as ...

Shares of Sangamo Therapeutics (NASDAQ:SGMO) rose 12% in post-market trading Tuesday after the company announced the FDA had ...

Founded with a mission to address the “last-mile” challenges in pain relief, Doloromics integrates artificial intelligence ...

Cardiometabolic disease biotech NeuroBo Pharmaceuticals is shaking up its corporate image with a complete rebrand. | ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved the medicine sparsentan (Filspari) to treat ...

AbbVie has announced the European Commission (EC) has granted marketing authorization for ELAHERE (mirvetuximab soravtansine) ...

Envista Holdings Corporation ("Envista") today announced that the company will participate in a fireside chat at the Evercore HealthCONx Conference on Tuesday, December 3, 2024 from 12:30 ? 1:15 pm ET ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) on Monday approved the medicine Filspari (sparsentan) from Vifor France to treat primary immunoglobulin A nephropathy (IgAN).

BD (Becton, Dickinson and Company) , a leading global medical technology company, today announced that it will present at the 7th Annual Evercore ISI HealthCONx Conference on Tuesday, December 3, 2024 ...

Discover Patanjali’s Madhugrit, an Ayurvedic diabetes solution blending natural herbs with scientific research to manage ...